Clinical trial
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
NCT05153408 is registered in ClinicalTrials.gov with Blueprint Medicines Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
- Lead sponsor
- Blueprint Medicines Corporation
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- January 13, 2022
- Completion date
- December 9, 2022
- Enrollment
- 20 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, antineoplastic agents, bronchial neoplasms, carcinoma, carcinoma, bronchogenic, carcinoma, non-small-cell lung, egf-r positive non-small cell lung cancer, egfr activating mutation, egfr c797a, egfr c797g, egfr c797s, egfr c797x, egfr exon 19 deletion, egfr gene mutation, egfr l858r, egfr mutation resulting in tyrosine kinase inhibitor resistance, lung diseases, lung neoplasm, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms, nerve tissue, non small cell lung cancer, protein kinase inhibitors, respiratory tract diseases, respiratory tract neoplasms, thoracic neoplasms